Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it was the COVID vaccine that made it a household name,” the analyst tells investors in a research note. The firm says that with the pandemic in the rear-view mirror, investor focus is increasingly shifting to BioNTech’s oncology business. It says 2025 is set up with potentially stock-moving read-outs for key assets, presenting “ample opportunity” for BioNTech to grow into the price target
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- NIH settlement ‘manageable headwind’ for BioNTech, Pfizer, says Morgan Stanley
- BioNTech to pay $467M in settlement agreement with University of Pennsylvania
- BioNTech to pay $791.5M in settlement agreement with the NIH
- BioNTech Settles Royalty Dispute with NIH for $791.5 Million
- BioNTech Settles Royalty Dispute with University of Pennsylvania